Ticker | Value | Shares | Price | Security | Type | Insider | Title | Return | Flags | Date |
|---|---|---|---|---|---|---|---|---|---|---|
| No transactions found | ||||||||||
Charles Cashion currently holds 42,424 shares of Conatus Pharmaceuticals Inc. (CNAT), valued at approximately $0. This represents their equity stake as Executive.
Based on SEC Form 4 filings, Charles Cashion has been a net buyer of CNAT stock. They have purchased $1.9K and sold $0 worth of shares.
Charles Cashion's most recent insider trade was on Jan 9, 2017, when they sold 42,424 shares at $0.99 per share.
Charles Cashion serves as Executive at Conatus Pharmaceuticals Inc. (CNAT). They have executed 29 insider transactions totaling $1.9K over their tenure at the company.
Charles Cashion holds the position of Executive at Conatus Pharmaceuticals Inc., where they are responsible for executive-level decision-making and strategic oversight. They have been associated with the company for 19 years and currently hold a stake valued at $0.
Charles Cashion has shown a buying trading pattern, with $1.9K in total purchases and $0 in total sales across all transactions. Their most recent activity indicates a tendency to accumulate shares.
The largest transaction by Charles Cashion was on Jan 9, 2017, when they sold $42.0K worth of CNAT shares. This transaction involved 42,424 shares at $0.99 per share.
Charles Cashion currently owns 42,424 shares of Conatus Pharmaceuticals Inc. (CNAT), with an estimated value of $0. This stake represents their equity holdings accumulated through purchases, awards, and option exercises.
All of Charles Cashion's SEC Form 4 insider trading filings are tracked on this page. Each transaction links directly to the official SEC EDGAR filing. Charles Cashion has 29 Form 4 filings on record as an insider at Conatus Pharmaceuticals Inc..
Set alerts for Charles Cashion and 40,000+ other insiders.